Cargando…

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients

Detalles Bibliográficos
Autor principal:	Banda, Malathi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486191/ https://www.ncbi.nlm.nih.gov/pubmed/26137569 http://dx.doi.org/10.1016/j.ebiom.2015.03.008

Ejemplares similares

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
por: Kopreski, M. S., et al.
Publicado: (1997)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids
por: Banda, Malathi, et al.
Publicado: (2020)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Escorting Ras
por: Zheng, Ze-Yi, et al.
Publicado: (2012)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
por: Verissimo, Carla S, et al.
Publicado: (2016)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers
por: Donahue, Katelyn L., et al.
Publicado: (2022)

COVID-19 and RAS: Unravelling an Unclear Relationship
por: D’Ardes, Damiano, et al.
Publicado: (2020)

Fast simultaneous detection of K-RAS mutations in colorectal cancer
por: Chang, Ya-Sian, et al.
Publicado: (2009)

Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation
por: Jin, Xi, et al.
Publicado: (2022)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS‐mutant metastatic colorectal cancer
por: Huang, Weizhen, et al.
Publicado: (2022)

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
por: Scharpf, Robert B., et al.
Publicado: (2022)

Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer
por: Xing, Mingzhao
Publicado: (2016)

Single-cell recordings reveal subpopulations that grow and generate resistance at bactericidal concentrations of antibiotics
por: Henriques-Normark, B., et al.
Publicado: (2023)

5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma
por: Nastasă, Cristina, et al.
Publicado: (2019)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

Conserved role of Ras-GEFs in promoting aging: from yeast to mice
por: Mirisola, Mario G., et al.
Publicado: (2011)

Mechanisms for regulation of RAS palmitoylation and plasma membrane trafficking in hematopoietic malignancies
por: Yu, Fang, et al.
Publicado: (2023)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
por: Kleiman, Laura B., et al.
Publicado: (2013)

Perioperative changes in lymphocyte subpopulations in patients undergoing surgery for colorectal cancer
por: Rubinkiewicz, Mateusz, et al.
Publicado: (2019)

RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer
por: Zhu, Liuying, et al.
Publicado: (2020)

Targeting mutant p53 in cancer: the latest insights
por: Di Agostino, Silvia, et al.
Publicado: (2019)

Spotlight on Accessory Proteins: RTK-RAS-MAPK Modulators as New Therapeutic Targets
por: Pudewell, Silke, et al.
Publicado: (2021)

The effects of mutant Ras proteins on the cell signalome
por: Takács, Tamás, et al.
Publicado: (2020)

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
por: Jin, Hua, et al.
Publicado: (2019)

An approach to addressing subpopulation considerations in systematic reviews: the experience of reviewers supporting the U.S. Preventive Services Task Force
por: Whitlock, Evelyn P., et al.
Publicado: (2017)

Inducible protein degradation as a strategy to identify Phosphoprotein Phosphatase 6 substrates in RAS-mutant colorectal cancer cells
por: Mariano, Natasha C., et al.
Publicado: (2023)

Inducible Protein Degradation as a Strategy to Identify Phosphoprotein Phosphatase 6 Substrates in RAS-Mutant Colorectal Cancer Cells
por: Mariano, Natasha C., et al.
Publicado: (2023)

Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer
por: El Sissy, Carine, et al.
Publicado: (2021)

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials
por: Stahler, Arndt, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jlmsat0tijafqeo9e5rq75ai0o